Posted by Michael Wonder on 06 Oct 2022
Maribavir for treating refractory or resistant cytomegalovirus infection after transplant
28 September 2022 - The Department of Health and Social Care has asked NICE to produce guidance on using maribavir in the NHS in England.
Maribavir is not recommended for the treatment of adults with a cytomegalovirus infection that is refractory or resistant to treatment including ganciclovir, valganciclovir, cidofovir or foscarnet in those who have had a haematopoietic stem cell transplant or solid organ transplant.
